# US 2008/0305079 A1 · Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305079 A1
- Document ID: US20080305079A1
- Status: Published application
- Kind: A1
- Application number: 12/159,929
- Filed: 2007-01-08
- Published: 2008-12-11
- Earliest claimed: 2006-01-06
- Assignees: Mount Sinai School of Medicine of New York University
- Inventors: Shu-Hsia Chen
- Web page: https://patentgrep.com/patent/US20080305079A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/13: Cyclosporins
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/2066: {IL-10}
- A61K 38/217: {IFN-gamma}
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel myeloid suppressor cells (MSCs) and to methods of isolating these MSCs are also included. The MSCs of the present invention can be used to treat or prevent autoimmune diseases or alloimmune responses. The MSCs of the present invention may also be used to reduce a T cell response, induce T regulatory cells, and produce T cell tolerance.

## Claims

### Claim 1

A method of treating an autoimmune disease in an individual, which method comprises administering a therapeutically effective amount of myeloid suppressor cells (MSCs) to the individual, wherein the MSCs have a Gr-1+/CD11b+ phenotype.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the autoimmune disease is type I diabetes.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the MSCs are autologous.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the method further comprises administering an inhibitor of MSC terminal differentiation.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the inhibitor inhibits the activity of GM-CSF, M-CSF, or IL-3.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the method further comprises altering SHIP signaling.

### Claim 7 (depends on 1)

The method according to claim 1 wherein the method further comprises increasing F4/80 expression.

### Claim 8 (depends on 1)

The method according to claim 1, further comprising the step of administering one or more autoantigens.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the MSCs are genetically modified to express or overexpress one or more autoantigens.

### Claim 10 (depends on 8)

The method according to claim 8, which method further comprises administering a cytokine.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the cytokine is IFN-γ, IL-10 or TGF-β.

### Claim 12 (depends on 1)

The method according to claim 1 wherein method further comprises administering an immunosuppressive drug.

### Claim 13 (depends on 12)

The method according to claim 12 wherein the immunosuppressive drug is cyclosporin, methotrexate, cyclophosphamide or tacrolimus.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the MSC phenotype further comprises CD115.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the MSC phenotype further comprises F4/80.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the phenotype includes at least one additional marker selected from the group consisting of CD31, c-kit, VEGF-receptor, and CD40.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the MSCs are genetically modified to overexpress Gr-1.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the MSCs are genetically modified to overexpress CD115.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the MSCs are genetically modified to overexpress F4/80.

### Claim 20

A method of treating an alloimmune response in an individual, which method comprises administering a therapeutically effective amount of myeloid suppressor cells (MSCs) to the individual, wherein the MSCs have a Gr-1+/CD11b+ phenotype.

### Claim 21 (depends on 20)

The method according to claim 20 wherein the alloimmune response is graft rejection.

### Claim 22 (depends on 20)

The method according to claim 20 wherein the alloimmune response is graft-versus-host disease (GVHD).

### Claim 23 (depends on 20)

The method according to claim 20 wherein the wherein MSCs are autologous.

### Claim 24 (depends on 20)

The method according to claim 20 wherein the method further comprises administering an inhibitor of MSC terminal differentiation.

### Claim 25 (depends on 24)

The method according to claim 24 wherein the inhibitor inhibits the activity of GMCSF, M-CSF, or IL-3.

### Claim 26 (depends on 20)

The method according to claim 20 wherein the method further comprises altering SHIP signaling.

### Claim 27 (depends on 20)

The method according to claim 20 wherein the method further comprises increasing F4/80 expression in MSCs.

### Claim 28 (depends on 20)

The method according to claim 20, further comprising the step of administering one or more autoantigens.

### Claim 29 (depends on 20)

The method according to claim 20 wherein the MSCs express one or more autoantigens.

### Claim 30 (depends on 28)

The method according to claim 28 wherein method further comprises administering a cytokine.

### Claim 31 (depends on 30)

The method according to claim 30 wherein the cytokine is IFN-γ, IL-10 or TGF-β.

### Claim 32 (depends on 20)

The method according to claim 20 wherein method further comprises administering an immunosuppressive drug.

### Claim 33 (depends on 32)

The method according to claim 32 wherein the immunosuppressive drug is selected from the group consisting of cyclosporin, methotrexate, cyclophosphamide, and tacrolimus.

### Claim 34 (depends on 20)

The method according to claim 20, wherein the MSC phenotype further comprises CD115.

### Claim 35 (depends on 20)

The method according to claim 20, wherein the MSC phenotype further comprises F4/80.

### Claim 36 (depends on 20)

The method according to claim 20, wherein phenotype includes at least one additional marker selected from the group consisting of CD31, c-kit, VEGF-receptor, and CD40.

### Claim 37 (depends on 20)

The method according to claim 20, wherein the MSCs are genetically modified to overexpress Gr-1.

### Claim 38 (depends on 20)

The method according to claim 20, wherein the MSCs are genetically modified to overexpress CD115.

### Claim 39 (depends on 20)

The method according to claim 20, wherein the MSCs are genetically modified to overexpress F4/80.

### Claim 40

A method of producing myeloid suppressor cells (MSCs), which method comprises culturing primary hematopoietic stem cells (HSCs) in the presence of stem-cell factor (SCF) in an amount and for a time sufficient to allow HSCs to differentiate into MSCs, wherein the MSCs have a Gr-1+/CD11b+ phenotype.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the MSC phenotype further comprises CD115.

### Claim 42 (depends on 40)

The method according to claim 40, wherein the MSC phenotype further comprises F4/80.

### Claim 43 (depends on 40)

The method according to claim 40, wherein the phenotype includes at least one additional marker selected from the group consisting of CD31, c-kit, VEGF-receptor, and CD40.

### Claim 44 (depends on 40)

The method according to claim 40, wherein the HSCs are genetically modified to overexpress Gr-1.

### Claim 45 (depends on 40)

The method according to claim 40, wherein the HSCs are genetically modified to overexpress CD115.

### Claim 46 (depends on 40)

The method according to claim 40, wherein the HSCs are genetically modified to overexpress F4/80.

### Claim 47 (depends on 40)

The method of claim 40 wherein the HSCs are further cultured in the presence of a factor selected from the group consisting of GM-CSF, M-CSF, G-CSF, Flit-3 ligand and tumor-conditioned medium.

### Claim 48 (depends on 40)

The method according to claim 40, further comprising the step of isolating the MSCs.

### Claim 49 (depends on 48)

The method according to claim 48 wherein the step of isolating is by gradient centrifugation.
